No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 9.6x · 10Y median 17.3x · 16th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 27
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T16:28:24.783Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Prelude Therapeutics Incorporated (PRLD) stock was $3.77 as of Oct 6, 2026, 12:25 PM EDT, down 0.13% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +155.3% · 3-year avg +10.7%/yr · 5-year avg -34.0%/yr
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs.
Biotechnology · Wilmington, DE
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-0.16
Revenue Est.
$27.75M
Last Quarter Results
EPS
$-0.14
vs Estimate
$-0.18
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1PRLD | $214.35M | $3.77 | -0.13% | +155.31% | -33.98% | N/A | N/A |
| 2NAGE | $214.51M | $2.69 | +0.50% | -61.15% | -15.72% | -1.06% | vs PRLD |
| 3NNNN | $215.07M | $4.90 | +1.45% | -84.84% | N/A | N/A | vs PRLD |
| 4CGEN | $212.27M | $2.25 | -2.81% | +41.48% | -18.39% | -9.42% | vs PRLD |
| 5ALEC | $217.61M | $1.96 | -1.51% | -39.91% | -39.17% | N/A | vs PRLD |
| 6LYEL | $218.26M | $8.91 | -1.80% | -48.74% | -48.18% | N/A | vs PRLD |
forward FY estimate
N/A
$5.70M
vs Estimate
$5.70M
Consensus Rating
Based on 5 analysts
Average Price Target
$9.20
+144.4% upside
Low
$6.00
Current
$3.77
High
$12.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 2 |
| Quarter ending Dec 2026 | $-0.18 | $-0.17 | $-0.16 | 2 |
| Quarter ending Mar 2027 | $-0.17 | $-0.17 | $-0.17 | 1 |
| Quarter ending Jun 2027 | $-0.16 | $-0.16 | $-0.16 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.14 | $-0.78 | $-0.42 | 3 |
| FY 2027 | $-1.16 | $-0.43 | $-0.10 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $27.75M | $27.75M | $27.75M | 2 |
| Quarter ending Dec 2026 | $2.67M | $2.67M | $2.67M | 2 |
| Quarter ending Mar 2027 | $4.63M | $4.63M | $4.63M | 1 |
| Quarter ending Jun 2027 | $5.99M | $5.99M | $5.99M | 1 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $14.45M | $39.22M | $63.98M | 3 |
| FY 2027 | $17.37M | $41.77M | $96.97M | 2 |
